Abstract CT039: Immunomodulatory effects of ceralasertib in combination with durvalumab in patients with NSCLC and progression on anti-PD-(L)1 treatment (HUDSON, NCT03334617)
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct039
Abstract: Background: Promising clinical activity has been described with the combination of ceralasertib (oral ATR inhibitor) and durvalumab (anti-PD-L1 mAb) in patients with NSCLC who have progressed on prior anti-PD-(L)1 immunotherapy (HUDSON, NCT03334617) (Besse et al.,… read more here.
Keywords: hudson nct03334617; durvalumab; combination; treatment ... See more keywords